Richard Lowenthal

You have to have a benefit to the community, benefit to the patient population.

And we believe NEFI achieves that very effectively.

by providing an option that is very simple.

It's easy to carry.

It's very easy to use.

As you know, we're using the same device we used for Narcan nasal.

That's now over the counter.

So the device is very simple to use without any training, just looking at the pictures.

And you can administer it very, very quickly.

It takes a fraction of a second to put it in the nose and push the plunger and you're done.

It's the child or yourself is medicated.

And that's really very, very important.

In addition, there's no needle.

So we take away that fear and that hesitancy, and that's really critical in getting really better clinical outcomes.

Now, again, we don't believe NEFI is better than injection.

We believe it's the same, and all of our data is showing it's working exactly the same as injection.

However, if you dose it sooner during the course of an allergic reaction, if you're less hesitant to administer it,

that will lead to better outcomes clinically.

And so we believe that differentiation is very well recognized by payers, and also certainly by patients and caregivers.

So we believe that that's what you need.